Bangkok Genomics Innovation PCL ROCE
The Return on Capital Employed (ROCE) of Bangkok Genomics Innovation PCL (BKGI.BK) as of Nov 15, 2026 is 7.66 %. In the previous year, Return on Capital Employed (ROCE) was 9.99 % — a change of -23.26% (lower).
Get this data via API
Financial Data API
ROCE
7.66 %
YoY
-23.26%
Last updated:
In 2025, Bangkok Genomics Innovation PCL's return on capital employed (ROCE) was 7.66 %, a -23.26% increase from the 9.99 % ROCE in the previous year.
The Bangkok Genomics Innovation PCL ROCE history
3 Years
10 Years
25 Years
Max
| YEAR | ROCE | YoY |
|---|---|---|
| 7.66 % | -23.26% | |
| 9.99 % | -28.28% | |
| 13.93 % | -56.74% | |
| 32.19 % | -54.94% | |
| 71.44 % | +125.86% | |
| 31.63 % | -21.81% | |
| 40.45 % | -146.34% | |
| -87.29 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bangkok Genomics Innovation PCL Stock analysis
ROCE Details
Unraveling Bangkok Genomics Innovation PCL's Return on Capital Employed (ROCE)
Bangkok Genomics Innovation PCL's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Bangkok Genomics Innovation PCL's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Bangkok Genomics Innovation PCL's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Bangkok Genomics Innovation PCL’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Bangkok Genomics Innovation PCL stock
Return on Capital Employed (ROCE) of Bangkok Genomics Innovation PCL is 7.66 % in 2025.
Return on Capital Employed (ROCE) of Bangkok Genomics Innovation PCL changed from 9.99 % to 7.66 %, representing a -23.26% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Bangkok Genomics Innovation PCL since 2006 – with annual values, charts, and detailed analysis.
ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Bangkok Genomics Innovation PCL with sector peers and the industry average to assess whether it is attractive.
To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Profitability — Bangkok Genomics Innovation PCL
All Key Metrics — Bangkok Genomics Innovation PCL
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth